Ge Rile, Yang Peng, Wen Bingtao
Department of Orthopedics, Peking University International Hospital, Haidian, Beijing 102206, P.R. China.
Oncol Lett. 2021 Jun;21(6):464. doi: 10.3892/ol.2021.12725. Epub 2021 Apr 12.
The present study aimed to determine the expression of the long non-coding RNA PTPRG-AS1 in patients with osteosarcoma, and to explore its role on the prognosis of patients and the process of osteosarcoma cell metastasis. Reverse transcription quantitative-PCR was performed to detect PTPRG-AS1 expression in osteosarcoma tumor tissues and cells (U2OS, SJSA1 and Saos-2), and normal tissues and cells (hFOB1.19). In addition, qPCR and western blotting were also used to detect mRNA and protein expression, respectively, whereas fluorescence in situ hybridization was used to locate the position of PTPRG-AS1 in osteosarcoma cells. Transwell assay was used to determine the migratory and invasive abilities of osteosarcoma cells. The results demonstrated that PTPRG-AS1 was highly expressed in osteosarcoma cells and tissues, which was compared with normal bone cells and adjacent healthy tissues. Furthermore, PTPRG-AS1 expression level in patients with osteosarcoma and lymph node metastasis or distal metastasis was elevated compared with normal tissues. In addition, the results from univariate and multivariate analyses demonstrated that PTPRG-AS1 expression level was significantly associated with Tumor-Node-Metastasis stage (P=0.025), lymph node metastasis (P=0.035) and distant metastasis (P=0.016) in patients with osteosarcoma. PTPRG-AS1 expression level (odd ratio, 3.012; 95% confidence interval, 1.564-4.219) was also considered as an independent risk factor affecting the 5-year survival rate of patients with osteosarcoma. Furthermore, the 5-year overall survival rate of patients with elevated PTPRG-AS1 expression level (56.36%) was significantly lower compared with patients with low PTPRG-AS1 expression level (78.43%). In addition, PTPRG-AS1 knockdown using small interfering RNA significantly decreased the invasive and migratory abilities of osteosarcoma cells . In summary, PTPRG-AS1 high expression in patients with osteosarcoma may predict the poor prognosis of patients, as PTPRG-AS may have a promoting effect on osteosarcoma cell metastasis.
本研究旨在确定长链非编码RNA PTPRG-AS1在骨肉瘤患者中的表达情况，并探讨其在患者预后及骨肉瘤细胞转移过程中的作用。采用逆转录定量聚合酶链反应检测骨肉瘤肿瘤组织和细胞（U2OS、SJSA1和Saos-2）以及正常组织和细胞（hFOB1.19）中PTPRG-AS1的表达。此外，还分别采用定量聚合酶链反应和蛋白质免疫印迹法检测mRNA和蛋白质表达，而荧光原位杂交用于定位PTPRG-AS1在骨肉瘤细胞中的位置。采用Transwell实验检测骨肉瘤细胞的迁移和侵袭能力。结果表明，与正常骨细胞和相邻健康组织相比，PTPRG-AS1在骨肉瘤细胞和组织中高表达。此外，与正常组织相比，骨肉瘤伴淋巴结转移或远处转移患者的PTPRG-AS1表达水平升高。另外，单因素和多因素分析结果表明，骨肉瘤患者中PTPRG-AS1表达水平与肿瘤-淋巴结-转移分期（P=0.025）、淋巴结转移（P=0.035）和远处转移（P=0.016）显著相关。PTPRG-AS1表达水平（比值比，3.012；95%置信区间，1.564-4.219）也被认为是影响骨肉瘤患者5年生存率的独立危险因素。此外，PTPRG-AS1表达水平升高患者的5年总生存率（56.36%）显著低于PTPRG-AS1表达水平低的患者（78.43%）。此外，使用小干扰RNA敲低PTPRG-AS1可显著降低骨肉瘤细胞的侵袭和迁移能力。总之，骨肉瘤患者中PTPRG-AS1高表达可能预示患者预后不良，因为PTPRG-AS可能对骨肉瘤细胞转移具有促进作用。
